Dialysis industry news

Stories from the dialysis comunity across the globe.



Fresenius Medical Care AG Co. Shares Gap Up on Analyst Upgrade (FMS) - sleekmoney PDF Print

Fresenius Medical Care AG & Co. (NYSE:FMS)’s share price gapped up before the market opened on Monday after RBC Capital raised their price target on the stock from $35.00 to $40.00, MarketBeat reports. The stock had previously closed at $40.45, but opened at $40.90. RBC Capital currently has a sector perform rating on the stock. Fresenius Medical Care AG & Co. shares last traded at $41.80, with a volume of 61,699 shares.

Separately, Commerzbank AG cut shares of Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Fresenius Medical Care AG & Co. currently has an average rating of “Hold” and a consensus target price of $39.03.

The firm has a market cap of $25.36 billion and a P/E ratio of 24.14. The company’s 50-day moving average price is $42.55 and its 200-day moving average price is $41.20.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the analysts’ consensus estimate of $0.42 by $0.02. The firm had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.13 billion. During the same quarter last year, the company posted $0.42 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. Equities research analysts anticipate that Fresenius Medical Care AG & Co. will post $1.76 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.image

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
New artificial blood vessel coating makes them resistant to thrombosis. PDF Print
EurekAlert: Scientists from ITMO University developed artificial blood vessels that are not susceptible to blood clot formation. The achievement was made possible by a new generation of drug-containing coating applied to the inner surface of the vessel. The results of the study were published in the Journal of Medicinal Chemistry.

...

 
AstraZeneca, Isis Pharmaceuticals to Develop Antisense Drugs for ... - Drug Discovery Development PDF Print
Drug Discovery & Development
Isis Pharmaceuticals, Inc. and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the ...
AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs ... PR Newswire (press release)
AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs

...

 
Tyrosine Kinase Inhibitors Appear Safe in CML Patients With CKD - Renal and Urology News PDF Print
August 03, 2015 In these patients, no further decline in GFR, regardless of TKI used.
In these patients, no further decline in GFR, regardless of TKI used.

(HealthDay News) -- Tyrosine kinase inhibitors (TKIs) appear to be safe in patients with chronic-phase (CP) chronic myeloid leukemia (CML) and chronic kidney disease (CKD), according to a study published online in Cancer.

Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, and colleagues examined the incidence of acute kidney injury (AKI) and CKD in 468 newly diagnosed imatinib-, dasatinib-, and nilotinib-treated CP CML patients. From the start of therapy to the last follow-up, the authors assessed molecular and cytogenetic response data, creatinine, and glomerular filtration rate (GFR).

The researchers found that 4% of patients had TKI-linked AKI. Compared with dasatinib and nilotinib, imatinib correlated with increased incidence of AKI (P = 0.014). Fourteen percent of patients developed CKD while receiving a TKI, of whom 84% were receiving imatinib (P < 0.001). The development of CKD correlated with imatinib, age, history of hypertension, and diabetes mellitus. Imatinib reduced GFR over time in patients with no CKD at baseline, while in patients with a history of CKD, imatinib did not cause a significant decline in GFR. After 3 months of treatment, imatinib, dasatinib, and nilotinib increased the mean GFR, with the most significant increase for nilotinib (P < 0.001).

"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Source

  1. Yilmaz, M; Lahoti, A; O'Brien, S; et al. Cancer; doi: 10.1002/cncr.29587.

...

 
Man who contracted rare bug during dialysis treated at Carlisle's Cumberland ... - News Star PDF Print

Medics at the Cumberland Infirmary in Carlisle have treated a patient who picked up a rare form of the E.coli bug while having dialysis in Egypt.

Cumberland Infirmary photo

A report on the man’s condition presented to senior managers at the hospital trust which treated him reveals that medics believe he caught the bug during a trip to the North African country in December last year.

None of his contacts was found to have caught the infection and the national watchdog Public Health England (PHE) has been told which dialysis centre in Egypt was involved.

The bug – known as CPE – was one of a number discussed in a report considered by the board of North Cumbria University Hospitals NHS Trust, which runs both the infirmary and Whitehaven’s West Cumbria Hospital.

The report goes on to mention other infections which have been dealt with by the trust’s two hospitals – including nine cases of the bug C-diff, six at the Cumberland Infirmary and three at the West Cumberland.

During 2014-15, says the report, there were 120 patients across north Cumbria with C-diff, and of these 19 died within 30 days of diagnosis.

Between April and June, there were 31 patients affected by the bug, and four of these died within 30 days.

PHE and the Lancashire Health Protection team confirmed that they were involved in investigating a case of CPE at North Cumbria University Hospitals NHS Trust.

Their investigation began in April and centred on Cumberland Infirmary and Whitehaven’s West Cumberland Hospital after routine testing uncovered the bug.

In line with national guidelines, people who may have come into contact with the patient were traced and no other cases were detected.

CPE belongs to a group of bacteria normally found in humans and animal guts. However if they enter blood or the urinary tract, they can cause very serious infections, said the statement. This can occur after an injury or via the use of medical devices such as catheters or intravenous drips where the skin is punctured.

CPE is the name given to gut bacteria which have developed resistance to an important group of antibiotics called Carbapenems. Infections caused by these CPE bacteria can still be treated with antibiotics but this is more difficult and may require combinations of drugs or use of older antibiotics.

Although some people can have active infection, others may carry the bacteria but have no symptoms. This bacteria can spread through faecal contamination so it is very important to practise good hand hygiene to stop it spreading to other vulnerable people. The incident was closed in June 2015.

...

 
<< Start < Prev 41 42 43 44 45 46 47 48 49 50 Next > End >>

Page 47 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.